Search Result

Results for "

Tubeimoside

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (1) Apoptosis (1) Autophagy (1) EGFR (1) HSP (1) Interleukin Related (3) NF-κB (1) NO Synthase (2) p38 MAPK (1) Reference Standards (3) RIG-I-like receptor (RLR) (1) SARS-CoV (1) TGF-β Receptor (1) VEGFR (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (1) Infection (1) Inflammation/Immunology (3) Metabolic Disease (2) Neurological Disease (1)

Inhibitors & Agonists

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-N0890

Tubeimoside I 4 Publications Verification Tubeimoside-1; Lobatoside-H	HSP NF-κB p38 MAPK Akt Autophagy Interleukin Related VEGFR	Cardiovascular Disease Inflammation/Immunology Cancer
Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases .

HY-N2542

Tubeimoside III 2 Publications Verification	Interleukin Related NO Synthase	Metabolic Disease Inflammation/Immunology Cancer
Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD₅₀ of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases .

HY-N0891

Tubeimoside II Tubeimoside-B	EGFR TGF-β Receptor RIG-I-like receptor (RLR) SARS-CoV	Infection Neurological Disease Cancer
Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with K_d values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180 .

HY-N0891R

Tubeimoside II (Standard) Tubeimoside-B (Standard)	Reference Standards Others	Cancer
Tubeimoside II (Standard) is the analytical standard of Tubeimoside II. This product is intended for research and analytical applications.

HY-N0890R

Tubeimoside I (Standard) Tubeimoside-1 (Standard); Lobatoside-H (Standard)	Reference Standards Apoptosis	Cancer
Tubeimoside I (Standard) is the analytical standard of Tubeimoside I. This product is intended for research and analytical applications. Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases .

HY-N2542R

Tubeimoside III (Standard)	Reference Standards Interleukin Related NO Synthase	Metabolic Disease Inflammation/Immunology Cancer
Tubeimoside III (Standard) is the analytical standard of Tubeimoside III (HY-N2542). This product is intended for research and analytical applications. Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD₅₀ of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases .

Tubeimoside I 4 Publications Verification Tubeimoside-1; Lobatoside-H	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Plants Bolbostemma paniculaum (Maxim)Franguet Disease Research Fields Source Classification Cancer	HSP NF-κB p38 MAPK Akt Autophagy Interleukin Related VEGFR
Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases .

Tubeimoside III 2 Publications Verification	Triterpenes Classification of Application Fields Terpenoids Cucurbitaceae Plants Bolbostemma paniculaum (Maxim)Franguet Inflammation/Immunology Disease Research Fields Source Classification	Interleukin Related NO Synthase
Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD₅₀ of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases .

Tubeimoside II Tubeimoside-B	Triterpenes Structural Classification other families Classification of Application Fields Terpenoids Plants Disease Research Fields Source Classification Cancer	EGFR TGF-β Receptor RIG-I-like receptor (RLR) SARS-CoV
Tubeimoside II is an orally active triterpenoid saponin and antiviral agent that binds to PACT/PRKRA with K_d values of 5.37 μM and 133.1 μM, respectively. Tubeimoside II inhibits oxidase-dependent EGFR activation and reduces TGF-β1-induced oxidative stress. Tubeimoside II activates the RIG-I signaling pathway and increases IFN-β secretion. Tubeimoside II suppresses TPA-induced ear edema, mouse sarcoma 180 growth, and TPA-induced skin tumor formation. Tubeimoside II exerts broad-spectrum antiviral activity against SARS-CoV-2, HCoV-OC43, and IAV-H1N1/FM1. Tubeimoside II can be used in research related to retinoblastoma, respiratory viral infections, skin tumors, and sarcoma 180 .

Tubeimoside II (Standard) Tubeimoside-B (Standard)	Triterpenes Structural Classification other families Terpenoids Plants Source Classification	Reference Standards Others
Tubeimoside II (Standard) is the analytical standard of Tubeimoside II. This product is intended for research and analytical applications.

Tubeimoside I (Standard) Tubeimoside-1 (Standard); Lobatoside-H (Standard)	Triterpenes Structural Classification Terpenoids Cucurbitaceae Plants Bolbostemma paniculaum (Maxim)Franguet Source Classification	Reference Standards Apoptosis
Tubeimoside I (Standard) is the analytical standard of Tubeimoside I. This product is intended for research and analytical applications. Tubeimoside I is an orally active HSPD1 inhibitor. Tubeimoside I inhibits NF-κB, MAPK, as well as regulates eNOS-VEGF. Tubeimoside I induces cytoprotective Autophagy via an Akt-mediated pathway. Tubeimoside I inhibits proinflammatory cytokine (IL-6 and IL-1β) production. Tubeimoside I exhibits anti-inflammatory activities. Tubeimoside I promotes angiogenesis and improves sepsis symptoms. Tubeimoside I is used in the research of inflammatory diseases, various cancers, sepsis and ischemic diseases .

Tubeimoside III (Standard)	Triterpenes Structural Classification Terpenoids Cucurbitaceae Plants Bolbostemma paniculaum (Maxim)Franguet Source Classification	Reference Standards Interleukin Related NO Synthase
Tubeimoside III (Standard) is the analytical standard of Tubeimoside III (HY-N2542). This product is intended for research and analytical applications. Tubeimoside III is a triterpenoid saponin. Tubeimoside III has anti-inflammatory and antitumor effects. Tubeimoside III has an LD₅₀ of 15 mg/kg by intraperitoneal injection in ICR mice. Tubeimoside III can be used for the research of tumors and inflammatory diseases .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature. Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.

BODIPY 493/503 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 1;16(1):1241. [Abstract]

MedchemExpress Validation 01

MedchemExpress Validation 03

Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred

MedchemExpress Validation 04

MedchemExpress Validation

We use cookies

MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website. Privacy and Cookie Policy

Name
Email *

	Sorry, but the email address you supplied was invalid.

Tubeimoside

Inhibitors & Agonists

NaturalProducts

Natural
Products